About Jaguar Health (NASDAQ:JAGX)
Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing novel, sustainably derived gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Canalevia is the company's lead animal prescription drug product candidate intended for treatment of various forms of diarrhea in dogs; and Equilevia is Jaguar's non-prescription product for total gut health in equine athletes. Canalevia and Equilevia contain ingredients isolated and purified from the Croton lechleri tree, which is sustainably harvested. In addition, the Company's products include Neonorm Calf and Neonorm Foal. Mytesi, Canalevia, Equilevia, and Neonorm are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar Health, Inc. is based in San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:JAGX
CUSIPN/A
Phone415-371-8300
Debt
Debt-to-Equity Ratio0.64%
Current Ratio0.25%
Quick Ratio0.11%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.36 million
Price / Sales6.33
Cash FlowN/A
Price / CashN/A
Book Value$0.16 per share
Price / Book1.02
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-21,960,000.00
Net Margins-502.65%
Return on Equity-188.56%
Return on Assets-61.60%
Miscellaneous
Employees36
Outstanding Shares168,320,000
Jaguar Health (NASDAQ:JAGX) Frequently Asked Questions
What is Jaguar Health's stock symbol?
Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX."
How were Jaguar Health's earnings last quarter?
Jaguar Health (NASDAQ:JAGX) announced its quarterly earnings results on Monday, November, 14th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.40) by $0.10. The biotechnology company earned $0.05 million during the quarter, compared to analysts' expectations of $0.10 million. Jaguar Health had a negative net margin of 502.65% and a negative return on equity of 188.56%. View Jaguar Health's Earnings History.
What price target have analysts set for JAGX?
2 analysts have issued twelve-month price objectives for Jaguar Health's stock. Their forecasts range from $2.00 to $2.00. On average, they anticipate Jaguar Health's stock price to reach $2.00 in the next twelve months. View Analyst Ratings for Jaguar Health.
Are investors shorting Jaguar Health?
Jaguar Health saw a increase in short interest in March. As of March 29th, there was short interest totalling 6,865,074 shares, an increase of 36.5% from the March 15th total of 5,027,707 shares. Based on an average trading volume of 6,371,217 shares, the short-interest ratio is presently 1.1 days. Currently, 8.9% of the shares of the stock are short sold.
Who are some of Jaguar Health's key competitors?
Some companies that are related to Jaguar Health include Versartis (VSAR), Pain Therapeutics (PTIE), Catabasis Pharmaceuticals (CATB), Zosano Pharma (ZSAN), Acerus Pharmaceuti (TRLPF), Immutep (IMMP), Novus Therapeutics (NVUS), Imprimis Pharmaceuticals (IMMY), AzurRx BioPharma (AZRX), Vivus (VVUS), IntelGenx Technologies (IGXT), Celsion (CLSN), Edge Therapeutics (EDGE), Capricor Therapeutics (CAPR), Evoke Pharma (EVOK), Lipocine (LPCN), Egalet (EGLT) and Chiasma (CHMA).
Who are Jaguar Health's key executives?
Jaguar Health's management team includes the folowing people:
- Ms. Lisa A. Conte, Founder, CEO & Exec. Director (Age 59)
- Ms. Karen S. Wright, Chief Financial Officer (Age 62)
- Dr. Pravin R. Chaturvedi, Chairman of Scientific Advisory Board & Pres (Age 55)
- Mr. Peter Hodge, Director of Investor Relations & Market Research
- Mr. Pete Riojas, National Sales Director
When did Jaguar Health IPO?
(JAGX) raised $22 million in an initial public offering on Wednesday, May 13th 2015. The company issued 3,200,000 shares at $7.00 per share. Aegis Capital Corp served as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.
Has Jaguar Health been receiving favorable news coverage?
Media coverage about JAGX stock has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Jaguar Health earned a daily sentiment score of 0.05 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 45.43 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Jaguar Health's major shareholders?
How do I buy shares of Jaguar Health?
Shares of JAGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Jaguar Health's stock price today?
One share of JAGX stock can currently be purchased for approximately $0.1639.
How big of a company is Jaguar Health?
Jaguar Health has a market capitalization of $28.78 million and generates $4.36 million in revenue each year. Jaguar Health employs 36 workers across the globe.
How can I contact Jaguar Health?
Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The biotechnology company can be reached via phone at 415-371-8300.
MarketBeat Community Rating for Jaguar Health (JAGX)
MarketBeat's community ratings are surveys of what our community members think about Jaguar Health and other stocks. Vote "Outperform" if you believe JAGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JAGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Jaguar Health (NASDAQ:JAGX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Jaguar Health in the last 12 months. Their average twelve-month price target is $2.00, suggesting that the stock has a possible upside of 1,120.26%. The high price target for JAGX is $2.00 and the low price target for JAGX is $2.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $2.00 | $2.00 | $2.00 | $2.00 |
| Price Target Upside: | 1,120.26% upside | 281.32% upside | 281.32% upside | 281.32% upside |
Jaguar Health (NASDAQ:JAGX) Consensus Price Target History
Jaguar Health (NASDAQ:JAGX) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/11/2017 | HC Wainwright | Set Price Target | Buy | $2.00 | High |  |
| 7/11/2017 | Rodman & Renshaw | Initiated Coverage | Buy -> Buy | $2.00 | High | |
| 6/13/2016 | Aegis | Reiterated Rating | Buy | $10.00 | N/A | |
(Data available from 4/20/2016 forward)
Jaguar Health (NASDAQ:JAGX) Earnings History and Estimates Chart
Jaguar Health (NASDAQ JAGX) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/20/2017 | Q3 2017 | | $0.13 | $1.61 million | $1.10 million | View | N/A | |
| 8/9/2017 | Q2 2017 | ($0.22) | ($0.12) | $1.34 million | $0.90 million | View | N/A | |
| 5/15/2017 | Q1 2017 | | ($0.28) | | $0.82 million | View | N/A | |
| 2/15/2017 | Q4 2016 | | ($0.28) | | $0.03 million | View | N/A | |
| 11/14/2016 | 9/30/2016 | ($0.40) | ($0.30) | $0.10 million | $0.05 million | View | N/A | |
| 8/15/2016 | Q2 2016 | ($0.42) | ($0.35) | $0.10 million | $0.02 million | View | N/A | |
| 5/10/2016 | Q1 2016 | ($0.49) | ($0.43) | $0.10 million | $0.04 million | View | N/A | |
| 3/29/2016 | Q4 2015 | | ($0.42) | | $0.06 million | View | N/A | |
| 11/13/2015 | Q3 2015 | ($0.49) | ($0.36) | $0.10 million | $0.08 million | View | N/A | |
| 8/13/2015 | Q2 2015 | | ($0.97) | | $0.06 million | View | N/A | |
| 6/26/2015 | Q1 2015 | | ($1.32) | | $0.06 million | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Jaguar Health (NASDAQ:JAGX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Jaguar Health (NASDAQ JAGX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.30%
Institutional Ownership Percentage: 12.43%
Jaguar Health (NASDAQ JAGX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/8/2016 | James J Bochnowski | Director | Buy | 160,000 | $2.50 | $400,000.00 | | |
(Data available from 1/1/2013 forward)
Jaguar Health (NASDAQ JAGX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Experts Highlight that Immune System Activation in Aging Patients Living with HIV/AIDS Triggers Effects Such as "Leaky Gut", Which Can Lead to Diarrhea
finance.yahoo.com - April 19 at 5:33 PM |
 | Form PRE 14A Jaguar Health, Inc. For: May 18
www.streetinsider.com - April 17 at 8:40 AM |
 | Jaguar Health Inc (JAGX) Sees Large Increase in Short Interest
www.americanbankingnews.com - April 13 at 2:10 AM |
| Jaguar Subsidiary Napo Pharmaceuticals Signs Agreement with the ADAP Crisis Task Force for Mytesi
finance.yahoo.com - April 10 at 5:24 PM |
| Recent Publications Indicate that Diarrhea is a Significant and Serious Issue in HIV
finance.yahoo.com - April 9 at 5:15 PM |
| Jaguar Health Appoints Jonathan B. Siegel to Board of Directors
finance.yahoo.com - April 2 at 5:21 PM |
| Jaguar Health Announces Up to $16.2 Million in Equity Financings in Separate Private Placement Investments, Including Investment by Sagard Capital Partners, L.P., to Continue Commercialization of FDA-Approved Mytesi
finance.yahoo.com - March 26 at 8:29 AM |
| ValuEngine Upgrades Jaguar Health (JAGX) to Sell
www.americanbankingnews.com - March 25 at 4:48 PM |
 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an ... - Business Wire (press release)
www.businesswire.com - March 14 at 8:44 AM |
 | Traders News Source: Jaguar Health, Pipeline Review , Analyst Ratings, Milestones
www.finanznachrichten.de - March 13 at 7:12 PM |
| Jaguar Health, Pipeline Review, Analyst Ratings, Milestones
finance.yahoo.com - March 13 at 7:12 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Jaguar Health, Inc.
finance.yahoo.com - March 13 at 7:12 PM |
| Why Jaguar Health Inc’s (NASDAQ:JAGX) CEO Pay Matters To You
finance.yahoo.com - March 13 at 7:12 PM |
| Jaguar Health, Inc. (JAGX)
finance.yahoo.com - March 10 at 8:29 AM |
| Today’s Research Reports on Stocks to Watch: Atossa Genetics and Jaguar Health
finance.yahoo.com - March 9 at 8:27 AM |
 | Jaguar Health Stock Explodes on FDA News
www.baystreet.ca - March 8 at 6:30 PM |
| FDA Indicates that Jaguar's Reasonable Expectation of Effectiveness Technical Section is Complete for Use of Canalevia for Treatment of Chemotherapy-Induced Diarrhea in Dogs
finance.yahoo.com - March 8 at 6:30 PM |
| Jaguar Health Subsidiary, Napo Pharmaceuticals, Signs Agreement with Pharmacy Services Provider "Transition Patient Services" to Establish Nationwide Pilot "Mytesi Direct" Program
finance.yahoo.com - March 2 at 6:02 PM |
| How Financially Strong Is Jaguar Health Inc (NASDAQ:JAGX)?
finance.yahoo.com - March 1 at 5:46 PM |
| Jaguar Health Inc (JAGX) Sees Significant Growth in Short Interest
www.americanbankingnews.com - February 9 at 5:00 PM |
| Jaguar Health (JAGX) & Shire Viropharma (VPHM) Head-To-Head Contrast
www.americanbankingnews.com - January 26 at 5:06 AM |
| at 4:15 pm Eastern Time to Provide Updates Regarding Jaguar and Napo Pharmaceuticals Commercial, Educational ... - Business Wire (press release)
www.businesswire.com - January 19 at 8:12 AM |
| Form 8-K Jaguar Health, Inc. For: Jan 18 - StreetInsider.com
www.streetinsider.com - January 19 at 8:12 AM |
| Napo Pharmaceuticals Comments on the Passing of HIV/AIDS Activist and Research Pioneer Dr. Mathilde Krim
finance.yahoo.com - January 18 at 7:09 PM |
| Jaguar Health to Host Conference Call Monday, January 22nd at 4:15 p.m. Eastern Time to Provide Updates Regarding Jaguar and Napo Pharmaceuticals Commercial, Educational & Product Development Activities and 2017 Results
finance.yahoo.com - January 18 at 7:09 PM |
| Critical Contrast: Cleveland BioLabs (CBLI) vs. Jaguar Health (JAGX)
www.americanbankingnews.com - January 10 at 3:08 AM |
| Jaguar Health Inc (NASDAQ:JAGX): Has Recent Earnings Growth Beaten Long-Term Trend?
finance.yahoo.com - January 6 at 3:55 PM |
| Jaguar Health, Inc. :JAGX-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018
finance.yahoo.com - January 1 at 10:48 AM |
| WallStreet Research(TM) Announces Release of Corporate Profile Coverage on Jaguar Health, Inc. (NASDAQ: JAGX)
finance.yahoo.com - December 26 at 12:03 PM |
| Jaguar Animal Health (JAGX) and Dubai-based Seed Mena Enter Collaboration Agreement for Equilevia - StreetInsider.com
www.streetinsider.com - December 14 at 11:17 AM |
| Jaguar Health and Dubai-based Seed Mena Enter Collaboration Agreement for Equilevia, Jaguar’s Personalized, Premium Product for Total Gut Health and Wellness in Horses
finance.yahoo.com - December 14 at 11:17 AM |
| New Survey Finds People Living With HIV With Diarrhea Often Suffer in Silence
finance.yahoo.com - December 12 at 11:44 AM |
| Zacks: Jaguar Health Inc (JAGX) Given $6.00 Consensus Price Target by Analysts
www.americanbankingnews.com - December 10 at 9:37 PM |
| Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Friday, December 15, 2017 - Business Wire (press release)
www.businesswire.com - December 1 at 6:18 PM |
| Keep Your Pants On Campaign From Napo Pharmaceuticals Chosen as Best HIV-Related Awareness Campaign of 2017 by Healthline
finance.yahoo.com - December 1 at 6:18 PM |
| Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Friday, December 15, 2017
finance.yahoo.com - December 1 at 6:18 PM |
| What You Must Know About Jaguar Health Inc’s (JAGX) Financial Strength
finance.yahoo.com - November 30 at 3:53 PM |
| Jaguar Animal Health (JAGX) Enters Share Purchase Agreement for 2M Shares and Common Stock Purchase ... - StreetInsider.com
www.streetinsider.com - November 29 at 11:10 AM |
| Jaguar Health Enters Share Purchase Agreement for 2 Million Shares and Common Stock Purchase Agreement Relating to a 10 Million Share Equity Line Offering With L2 Capital, LLC
finance.yahoo.com - November 27 at 5:18 PM |
| Jaguar Health Files First Quarterly Earnings Report Since July 2017 Merger with Napo Pharmaceuticals - Business Wire (press release)
www.businesswire.com - November 22 at 1:19 AM |
| Jaguar Health Files First Quarterly Earnings Report Since July 2017 Merger with Napo Pharmaceuticals
finance.yahoo.com - November 21 at 1:58 AM |
| Jaguar Health Presenting Neonorm Calf at Western Organic Dairy ... - Business Wire (press release)
www.businesswire.com - November 17 at 8:19 AM |
 | Jaguar Health's (JAGX) CEO Lisa Conte on First Post-Merger Earnings Call - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 17 at 8:19 AM |
| Dr. Roscoe M. Moore Jr., DVM, MPH, Ph.D., DSc Joins Napo Pharmaceuticals Scientific Advisory Board for HIV for Mytesi, Napo’s FDA-Approved Human Prescription Drug
finance.yahoo.com - November 17 at 8:19 AM |
| Jaguar Health Presenting Neonorm Calf at Western Organic Dairy Producers Alliance Conference
finance.yahoo.com - November 17 at 8:19 AM |
| Is Jaguar Health Inc (JAGX) A Healthcare Industry Laggard Or Leader?
finance.yahoo.com - November 15 at 3:28 AM |
| Today’s Jaguar Health Conference Call Moved to 5:45 p.m. Eastern Time
finance.yahoo.com - November 15 at 3:28 AM |
| Year-to-Date Gross Sales for Mytesi, the FDA-Approved Human Prescription Drug Product of Jaguar Health’s Wholly-Owned Subsidiary, Napo Pharmaceuticals, Total $2.8 Million
finance.yahoo.com - November 15 at 3:28 AM |
| Jaguar Health to Host Earnings Conference Call Tuesday, November 14th at 4:30 p.m. Eastern Time
finance.yahoo.com - November 11 at 2:14 PM |
| Analyzing Jaguar Animal Health (JAGX) and Its Peers
www.americanbankingnews.com - November 11 at 1:28 AM |
Jaguar Health (NASDAQ:JAGX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Jaguar Health (NASDAQ:JAGX) Income Statement, Balance Sheet and Cash Flow Statement
Jaguar Health (NASDAQ JAGX) Stock Chart for Friday, April, 20, 2018
Loading chart…
